Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity.
Flavanones
Hesperitin
Mitochondrial dynamics
Multiple myeloma
Naringenin
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
received:
25
01
2024
accepted:
21
02
2024
medline:
28
2
2024
pubmed:
28
2
2024
entrez:
27
2
2024
Statut:
epublish
Résumé
Mitochondrial alterations, often dependent on unbalanced mitochondrial dynamics, feature in the pathobiology of human cancers, including multiple myeloma (MM). Flavanones are natural flavonoids endowed with mitochondrial targeting activities. Herein, we investigated the capability of Hesperetin (Hes) and Naringenin (Nar), two aglycones of Hesperidin and Naringin flavanone glycosides, to selectively target Drp1, a pivotal regulator of mitochondrial dynamics, prompting anti-MM activity. Molecular docking analyses were performed on the crystallographic structure of Dynamin-1-like protein (Drp1), using Hes and Nar molecular structures. Cell viability and apoptosis were assessed in MM cell lines, or in co-culture systems with primary bone marrow stromal cells, using Cell Titer Glo and Annexin V-7AAD staining, respectively; clonogenicity was determined using methylcellulose colony assays. Transcriptomic analyses were carried out using the Ion AmpliSeq™ platform; mRNA and protein expression levels were determined by quantitative RT-PCR and western blotting, respectively. Mitochondrial architecture was assessed by transmission electron microscopy. Real time measurement of oxygen consumption was performed by high resolution respirometry in living cells. In vivo anti-tumor activity was evaluated in NOD-SCID mice subcutaneously engrafted with MM cells. Hes and Nar were found to accommodate within the GTPase binding site of Drp1, and to inhibit Drp1 expression and activity, leading to hyperfused mitochondria with reduced OXPHOS. In vitro, Hes and Nar reduced MM clonogenicity and viability, even in the presence of patient-derived bone marrow stromal cells, triggering ER stress and apoptosis. Interestingly, Hes and Nar rewired MM cell metabolism through the down-regulation of master transcriptional activators (SREBF-1, c-MYC) of lipogenesis genes. An extract of Tacle, a Citrus variety rich in Hesperidin and Naringin, was capable to recapitulate the phenotypic and molecular perturbations of each flavanone, triggering anti-MM activity in vivo. Hes and Nar inhibit proliferation, rewire the metabolism and induce apoptosis of MM cells via antagonism of the mitochondrial fission driver Drp1. These results provide a framework for the development of natural anti-MM therapeutics targeting aberrant mitochondrial dependencies.
Sections du résumé
BACKGROUND
BACKGROUND
Mitochondrial alterations, often dependent on unbalanced mitochondrial dynamics, feature in the pathobiology of human cancers, including multiple myeloma (MM). Flavanones are natural flavonoids endowed with mitochondrial targeting activities. Herein, we investigated the capability of Hesperetin (Hes) and Naringenin (Nar), two aglycones of Hesperidin and Naringin flavanone glycosides, to selectively target Drp1, a pivotal regulator of mitochondrial dynamics, prompting anti-MM activity.
METHODS
METHODS
Molecular docking analyses were performed on the crystallographic structure of Dynamin-1-like protein (Drp1), using Hes and Nar molecular structures. Cell viability and apoptosis were assessed in MM cell lines, or in co-culture systems with primary bone marrow stromal cells, using Cell Titer Glo and Annexin V-7AAD staining, respectively; clonogenicity was determined using methylcellulose colony assays. Transcriptomic analyses were carried out using the Ion AmpliSeq™ platform; mRNA and protein expression levels were determined by quantitative RT-PCR and western blotting, respectively. Mitochondrial architecture was assessed by transmission electron microscopy. Real time measurement of oxygen consumption was performed by high resolution respirometry in living cells. In vivo anti-tumor activity was evaluated in NOD-SCID mice subcutaneously engrafted with MM cells.
RESULTS
RESULTS
Hes and Nar were found to accommodate within the GTPase binding site of Drp1, and to inhibit Drp1 expression and activity, leading to hyperfused mitochondria with reduced OXPHOS. In vitro, Hes and Nar reduced MM clonogenicity and viability, even in the presence of patient-derived bone marrow stromal cells, triggering ER stress and apoptosis. Interestingly, Hes and Nar rewired MM cell metabolism through the down-regulation of master transcriptional activators (SREBF-1, c-MYC) of lipogenesis genes. An extract of Tacle, a Citrus variety rich in Hesperidin and Naringin, was capable to recapitulate the phenotypic and molecular perturbations of each flavanone, triggering anti-MM activity in vivo.
CONCLUSION
CONCLUSIONS
Hes and Nar inhibit proliferation, rewire the metabolism and induce apoptosis of MM cells via antagonism of the mitochondrial fission driver Drp1. These results provide a framework for the development of natural anti-MM therapeutics targeting aberrant mitochondrial dependencies.
Identifiants
pubmed: 38413989
doi: 10.1186/s12967-024-05013-0
pii: 10.1186/s12967-024-05013-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
208Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG24449
Informations de copyright
© 2024. The Author(s).
Références
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos M-V, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
pubmed: 28726797
doi: 10.1038/nrdp.2017.46
Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol. 2007;20:797–816.
pubmed: 18070720
pmcid: 3445017
doi: 10.1016/j.beha.2007.09.008
Alsayyah C, Ozturk O, Cavellini L, Belgareh-Touzé N, Cohen MM. The regulation of mitochondrial homeostasis by the ubiquitin proteasome system. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 2020;1861:148302.
Nair R, Gupta P, Shanmugam M. Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy. Front Oncol. 2022. https://doi.org/10.3389/fonc.2022.1000106 .
doi: 10.3389/fonc.2022.1000106
pubmed: 37025252
pmcid: 9751310
Zhan X, Yu W, Franqui-Machin R, Bates ML, Nadiminti K, Cao H, et al. Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma. Oncotarget. 2017;8:111213–24.
pubmed: 29340048
pmcid: 5762316
doi: 10.18632/oncotarget.22740
Giacomello M, Pyakurel A, Glytsou C, Scorrano L. The cell biology of mitochondrial membrane dynamics. Nat Rev Mol Cell Biol. 2020;21:204–24.
pubmed: 32071438
doi: 10.1038/s41580-020-0210-7
Gallo Cantafio ME, Torcasio R, Viglietto G, Amodio N. Non-coding RNA-dependent regulation of mitochondrial dynamics in cancer pathophysiology. Noncoding RNA. 2023;9:16.
pubmed: 36827549
pmcid: 9964195
Rocca C, Soda T, De Francesco EM, Fiorillo M, Moccia F, Viglietto G, et al. Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer. J Transl Med. 2023;21:635.
pubmed: 37726810
pmcid: 10507834
doi: 10.1186/s12967-023-04498-5
Banerjee R, Mukherjee A, Nagotu S. Mitochondrial dynamics and its impact on human health and diseases: inside the DRP1 blackbox. J Mol Med. 2022;100:1–21.
pubmed: 34657190
doi: 10.1007/s00109-021-02150-7
Liu A, Lv Z, Yan Z, Wu X, Yan L, Sun L, et al. Association of mitochondrial homeostasis and dynamic balance with malignant biological behaviors of gastrointestinal cancer. J Transl Med. 2023;21:27.
pubmed: 36647167
pmcid: 9843870
doi: 10.1186/s12967-023-03878-1
Zhang Y, Yang B, Tu C, Ping Y, Chen S, Wu T, et al. Mitochondrial impairment and downregulation of Drp1 phosphorylation underlie the antiproliferative and proapoptotic effects of alantolactone on oral squamous cell carcinoma cells. J Transl Med. 2023;21:328.
pubmed: 37198593
pmcid: 10193726
doi: 10.1186/s12967-023-04188-2
Xu X, Wang X, Chen Q, Zheng A, Li D, Meng Z, et al. Sp1 promotes tumour progression by remodelling the mitochondrial network in cervical cancer. J Transl Med. 2023;21:307.
pubmed: 37147632
pmcid: 10163764
doi: 10.1186/s12967-023-04141-3
Du F, Yang L, Liu J, Wang J, Fan L, Duangmano S, et al. The role of mitochondria in the resistance of melanoma to PD-1 inhibitors. J Transl Med. 2023;21:345.
pubmed: 37221594
pmcid: 10207731
doi: 10.1186/s12967-023-04200-9
Huang P, Fan X, Yu H, Zhang K, Li H, Wang Y, et al. Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer. J Transl Med. 2023;21:94.
pubmed: 36750868
pmcid: 9906873
doi: 10.1186/s12967-022-03851-4
Cai J, Wang J, Huang Y, Wu H, Xia T, Xiao J, et al. ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells. Cell Death Dis. 2016;7:e2459–e2459.
pubmed: 27831567
pmcid: 5260898
doi: 10.1038/cddis.2016.370
D’Aquila P, Ronchetti D, Gallo Cantafio ME, Todoerti K, Taiana E, Fabiani F, et al. Epigenetic regulation of mitochondrial quality control genes in multiple myeloma: a sequenom MassARRAY pilot investigation on HMCLs. J Clin Med. 2021;10:1295.
pubmed: 33801014
pmcid: 8004002
doi: 10.3390/jcm10061295
Huang T, Chang C, Chien C, Huang G, Chen Y, Su L, et al. DRP1 contributes to head and neck cancer progression and induces glycolysis through modulated FOXM1/MMP12 axis. Mol Oncol. 2022;16:2585–606.
pubmed: 35313071
pmcid: 9251862
doi: 10.1002/1878-0261.13212
Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79:629–61.
pubmed: 26852623
doi: 10.1021/acs.jnatprod.5b01055
Jöhrer K, Ҫiҫek SS. Multiple myeloma inhibitory activity of plant natural products. Cancers. 2021;13:2678.
pubmed: 34072312
pmcid: 8198565
doi: 10.3390/cancers13112678
Juli G, Oliverio M, Bellizzi D, Gallo Cantafio ME, Grillone K, Passarino G, et al. Anti-tumor activity and epigenetic impact of the polyphenol oleacein in multiple myeloma. Cancers. 2019;11:990.
pubmed: 31315220
pmcid: 6679356
doi: 10.3390/cancers11070990
Todoerti K, Gallo Cantafio ME, Oliverio M, Juli G, Rocca C, Citraro R, et al. Oleil hydroxytyrosol (HTOL) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells. Int J Mol Sci. 2021;22:11639.
pubmed: 34769070
pmcid: 8584245
doi: 10.3390/ijms222111639
Ambrosio FA, Costa G, Gallo Cantafio ME, Torcasio R, Trapasso F, Alcaro S, et al. Natural agents as novel potential source of proteasome inhibitors with anti-tumor activity: focus on multiple myeloma. Molecules. 2023;28:1438.
pubmed: 36771100
pmcid: 9919276
doi: 10.3390/molecules28031438
Li G, Ding K, Qiao Y, Zhang L, Zheng L, Pan T, et al. Flavonoids regulate inflammation and oxidative stress in cancer. Molecules. 2020;25:5628.
pubmed: 33265939
pmcid: 7729519
doi: 10.3390/molecules25235628
Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J. Flavonoids as anticancer agents. Nutrients. 2020;12:457.
pubmed: 32059369
pmcid: 7071196
doi: 10.3390/nu12020457
Wenger J, Klinglmayr E, Fröhlich C, Eibl C, Gimeno A, Hessenberger M, et al. Functional mapping of human dynamin-1-Like GTPase domain based on X-ray structure analyses. PLoS ONE. 2013;8: e71835.
pubmed: 23977156
pmcid: 3747075
doi: 10.1371/journal.pone.0071835
Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform. 2012;4:17.
pubmed: 22889332
pmcid: 3542060
doi: 10.1186/1758-2946-4-17
Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–61.
pubmed: 19499576
pmcid: 3041641
doi: 10.1002/jcc.21334
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639–62.
doi: 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein–ligand interaction profiler. Nucleic Acids Res. 2015;43:W443–7.
pubmed: 25873628
pmcid: 4489249
doi: 10.1093/nar/gkv315
Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, et al. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016;15:1364–75.
pubmed: 27196750
doi: 10.1158/1535-7163.MCT-15-0985
Casacchia T, Occhiuzzi MA, Grande F, Rizzuti B, Granieri MC, Rocca C, et al. A pilot study on the nutraceutical properties of the Citrus hybrid Tacle® as a dietary source of polyphenols for supplementation in metabolic disorders. J Funct Foods. 2019;52:370–81.
doi: 10.1016/j.jff.2018.11.030
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. The Innovation. 2021;2:100141.
pubmed: 34557778
pmcid: 8454663
doi: 10.1016/j.xinn.2021.100141
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B. 1995;57:289–300.
Morelli E, Hunter ZR, Fulciniti M, Gullà A, Perrotta ID, Zuccalà V, et al. Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia. Exp Hematol Oncol. 2022;11:54.
pubmed: 36096954
pmcid: 9469525
doi: 10.1186/s40164-022-00305-x
Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, et al. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018;32:1948–57.
pubmed: 29487387
pmcid: 6127082
doi: 10.1038/s41375-018-0067-3
Amodio N, Gallo Cantafio M, Botta C, Agosti V, Federico C, Caracciolo D, et al. Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma. Cancers. 2019;11:236.
pubmed: 30781685
pmcid: 6406286
doi: 10.3390/cancers11020236
Day AJ, Cañada FJ, Dı́az JC, Kroon PA, Mclauchlan R, Faulds CB, et al. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett. 2000;468:166–70.
pubmed: 10692580
doi: 10.1016/S0014-5793(00)01211-4
Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJC, Morgan MRA, et al. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β-glucosidase activity. FEBS Lett. 1998;436:71–5.
pubmed: 9771896
doi: 10.1016/S0014-5793(98)01101-6
You Y, He Q, Lu H, Zhou X, Chen L, Liu H, et al. Silibinin induces G2/M cell cycle arrest by activating Drp1-dependent mitochondrial fission in cervical cancer. Front Pharmacol. 2020. https://doi.org/10.3389/fphar.2020.00271 .
doi: 10.3389/fphar.2020.00271
pubmed: 33568990
pmcid: 7770224
Wu D, Dasgupta A, Chen K, Neuber-Hess M, Patel J, Hurst TE, et al. Identification of novel dynamin-related protein 1 (Drp1) GTPase inhibitors: Therapeutic potential of Drpitor1 and Drpitor1a in cancer and cardiac ischemia-reperfusion injury. FASEB J. 2020;34:1447–64.
pubmed: 31914641
doi: 10.1096/fj.201901467R
Yu M, Nguyen ND, Huang Y, Lin D, Fujimoto TN, Molkentine JM, et al. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight. 2019;4.
Paradzik T, Bandini C, Mereu E, Labrador M, Taiana E, Amodio N, et al. The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma. Cancers. 2021;13:1235.
pubmed: 33799793
pmcid: 8000754
doi: 10.3390/cancers13061235
Russo C, Maugeri A, De Luca L, Gitto R, Lombardo GE, Musumeci L, et al. The SIRT2 pathway is involved in the antiproliferative effect of flavanones in human leukemia monocytic THP-1 cells. Biomedicines. 2022;10:2383.
pubmed: 36289647
pmcid: 9598940
doi: 10.3390/biomedicines10102383
Markovina S, Callander NS, O’Connor SL, Xu G, Shi Y, Leith CP, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells. Mol Cancer. 2010;9:176.
pubmed: 20604947
pmcid: 3095250
doi: 10.1186/1476-4598-9-176
Grande F, Occhiuzzi MA, Perri MR, Ioele G, Rizzuti B, Statti G, et al. Polyphenols from citrus Tacle® extract endowed with HMGCR inhibitory activity: an antihypercholesterolemia natural remedy. Molecules. 2021;26:5718.
pubmed: 34577189
pmcid: 8470345
doi: 10.3390/molecules26185718
Wu D, Yang Y, Hou Y, Zhao Z, Liang N, Yuan P, et al. Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 1. Cancer Commun. 2022;42:37–55.
doi: 10.1002/cac2.12247
Gouw AM, Margulis K, Liu NS, Raman SJ, Mancuso A, Toal GG, et al. The MYC oncogene cooperates with sterol-regulated element-binding protein to regulate lipogenesis essential for neoplastic growth. Cell Metab. 2019;30:556-572.e5.
pubmed: 31447321
pmcid: 6911354
doi: 10.1016/j.cmet.2019.07.012
Tirinato L, Pagliari F, Limongi T, Marini M, Falqui A, Seco J, et al. An overview of lipid droplets in cancer and cancer stem cells. Stem Cells Int. 2017;2017:1–17.
doi: 10.1155/2017/1656053
Soriano GP, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N, et al. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia. 2016;30:2198–207.
pubmed: 27118406
pmcid: 5097071
doi: 10.1038/leu.2016.102
Giallongo C, Dulcamare I, Tibullo D, Del Fabro V, Vicario N, Parrinello N, et al. CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis. 2022;11:6.
pubmed: 35064098
pmcid: 8782911
doi: 10.1038/s41389-022-00380-z
Lv J, Sun H, Gong L, Wei X, He Y, Yu Z, et al. Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.1077768 .
doi: 10.3389/fimmu.2022.1077768
pubmed: 36741358
pmcid: 9812954
Barbato A, Scandura G, Puglisi F, Cambria D, La Spina E, Palumbo GA, et al. Mitochondrial bioenergetics at the onset of drug resistance in hematological malignancies: an overview. Front Oncol. 2020. https://doi.org/10.3389/fonc.2020.604143 .
doi: 10.3389/fonc.2020.604143
pubmed: 33409153
pmcid: 7779674
Tilokani L, Nagashima S, Paupe V, Prudent J. Mitochondrial dynamics: overview of molecular mechanisms. Essays Biochem. 2018;62:341–60.
pubmed: 30030364
pmcid: 6056715
doi: 10.1042/EBC20170104
Wang Y, Zeng Z, Zeng Z, Chu G, Shan X. Elevated CHCHD4 orchestrates mitochondrial oxidative phosphorylation to disturb hypoxic pulmonary hypertension. J Transl Med. 2023;21:464.
pubmed: 37438854
pmcid: 10339524
doi: 10.1186/s12967-023-04268-3
Zheng Y, Wang S, Wu J, Wang Y. Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy. J Transl Med. 2023;21:510.
pubmed: 37507803
pmcid: 10375703
doi: 10.1186/s12967-023-04367-1
Zhao L, Hu C, Zhang P, Jiang H, Chen J. Mesenchymal stem cell therapy targeting mitochondrial dysfunction in acute kidney injury. J Transl Med. 2019;17:142.
pubmed: 31046805
pmcid: 6498508
doi: 10.1186/s12967-019-1893-4
Bustamante-Barrientos FA, Luque-Campos N, Araya MJ, Lara-Barba E, de Solminihac J, Pradenas C, et al. Mitochondrial dysfunction in neurodegenerative disorders: potential therapeutic application of mitochondrial transfer to central nervous system-residing cells. J Transl Med. 2023;21:613.
pubmed: 37689642
pmcid: 10493034
doi: 10.1186/s12967-023-04493-w
Liu Y, Yang H, Luo N, Fu Y, Qiu F, Pan Z, et al. An Fgr kinase inhibitor attenuates sepsis-associated encephalopathy by ameliorating mitochondrial dysfunction, oxidative stress, and neuroinflammation via the SIRT1/PGC-1α signaling pathway. J Transl Med. 2023;21:486.
pubmed: 37475042
pmcid: 10360347
doi: 10.1186/s12967-023-04345-7
Diane A, Al-Shukri NA, Bin Abdul Mu-u-min R, Al-Siddiqi HH. β-cell mitochondria in diabetes mellitus: a missing puzzle piece in the generation of hPSC-derived pancreatic β-cells? J Transl Med. 2022;20:163.
pubmed: 35397560
pmcid: 8994301
doi: 10.1186/s12967-022-03327-5
Chen X, Ji Y, Liu R, Zhu X, Wang K, Yang X, et al. Mitochondrial dysfunction: roles in skeletal muscle atrophy. J Transl Med. 2023;21:503.
pubmed: 37495991
pmcid: 10373380
doi: 10.1186/s12967-023-04369-z
Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell. 2008;14:193–204.
pubmed: 18267088
pmcid: 2267902
doi: 10.1016/j.devcel.2007.11.019
Lei X, Lin H, Wang J, Ou Z, Ruan Y, Sadagopan A, et al. Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression. Nat Commun. 2022;13:3882.
pubmed: 35794100
pmcid: 9259736
doi: 10.1038/s41467-022-31417-x
Bordt EA, Clerc P, Roelofs BA, Saladino AJ, Tretter L, Adam-Vizi V, et al. The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev Cell. 2017;40:583-594.e6.
pubmed: 28350990
pmcid: 5398851
doi: 10.1016/j.devcel.2017.02.020
Yan Q, Liu S, Sun Y, Chen C, Yang S, Lin M, et al. Targeting oxidative stress as a preventive and therapeutic approach for cardiovascular disease. J Transl Med. 2023;21:519.
pubmed: 37533007
pmcid: 10394930
doi: 10.1186/s12967-023-04361-7
Xing W, Gao W, Zhao Z, Xu X, Bu H, Su H, et al. Dietary flavonoids intake contributes to delay biological aging process: analysis from NHANES dataset. J Transl Med. 2023;21:492.
pubmed: 37480074
pmcid: 10362762
doi: 10.1186/s12967-023-04321-1
Li Y-X, Lu Y-P, Tang D, Hu B, Zhang Z-Y, Wu H-W, et al. Anthocyanin improves kidney function in diabetic kidney disease by regulating amino acid metabolism. J Transl Med. 2022;20:510.
pubmed: 36335368
pmcid: 9636632
doi: 10.1186/s12967-022-03717-9
Zang M, Hu L, Fan Z, Wang H, Zhu Z, Cao S, et al. Luteolin suppresses gastric cancer progression by reversing epithelial-mesenchymal transition via suppression of the Notch signaling pathway. J Transl Med. 2017;15:52.
pubmed: 28241766
pmcid: 5327575
doi: 10.1186/s12967-017-1151-6
Sousa C, Duarte D, Silva-Lima B, Videira M. Repurposing natural dietary flavonoids in the modulation of cancer tumorigenesis: decrypting the molecular targets of naringenin, hesperetin and myricetin. Nutr Cancer. 2022;74:1188–202.
pubmed: 34739306
doi: 10.1080/01635581.2021.1955285
Marchese E, Gallo Cantafio ME, Ambrosio FA, Torcasio R, Valentino I, Trapasso F, et al. New insights for polyphenolic compounds as naturally inspired proteasome inhibitors. Pharmaceuticals. 2023;16:1712.
pubmed: 38139838
pmcid: 10747119
doi: 10.3390/ph16121712
Raimondi L, De Luca A, Giavaresi G, Barone A, Tagliaferri P, Tassone P, et al. Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. Curr Med Chem. 2020;27:187–215.
pubmed: 29956610
doi: 10.2174/0929867325666180629153141
Pojero F, Poma P, Spanò V, Montalbano A, Barraja P, Notarbartolo M. Targeting multiple myeloma with natural polyphenols. Eur J Med Chem. 2019;180:465–85.
pubmed: 31330448
doi: 10.1016/j.ejmech.2019.07.041
Rapisarda P, Bellomo SE, Fabroni S, Russo G. Juice quality of two new Mandarin-like hybrids (Citrus clementina Hort. ex Tan x Citrus sinensis L. Osbeck) containing anthocyanins. J Agric Food Chem. 2008;56:2074–8.
pubmed: 18298061
doi: 10.1021/jf072616e
Rapisarda P, Fabroni S, Peterek S, Russo G, Mock H-P. Juice of New citrus hybrids (Citrus clementina Hort. ex Tan.×C. sinensis L. Osbeck) as a source of natural antioxidants. Food Chem. 2009;117:212–8.
doi: 10.1016/j.foodchem.2009.03.101
Adhikary A, Mukherjee A, Banerjee R, Nagotu S. DRP1: at the crossroads of dysregulated mitochondrial dynamics and altered cell signaling in cancer cells. ACS Omega. 2023;8:45208–23.
pubmed: 38075775
pmcid: 10701729
doi: 10.1021/acsomega.3c06547
Song J, Yi X, Gao R, Sun L, Wu Z, Zhang S, et al. Impact of Drp1-mediated mitochondrial dynamics on T cell immune modulation. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.873834 .
doi: 10.3389/fimmu.2022.873834
pubmed: 36741376
pmcid: 9811195
Solimando AG, Da Vià MC, Leone P, Borrelli P, Croci GA, Tabares P, et al. Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. Haematologica. 2020;106:1943–56.
pmcid: 8252928
doi: 10.3324/haematol.2019.239913
Solimando AG, Da Vià MC, Bolli N, Steinbrunn T. The route of the malignant plasma cell in its survival Niche: exploring “multiple myelomas.” Cancers. 2022;14:3271.
pubmed: 35805041
pmcid: 9265748
doi: 10.3390/cancers14133271
Casadonte R, Kriegsmann J, Kriegsmann M, Kriegsmann K, Torcasio R, Gallo Cantafio ME, et al. A comparison of different sample processing protocols for MALDI imaging mass spectrometry analysis of formalin-fixed multiple myeloma cells. Cancers. 2023;15:974.
pubmed: 36765932
pmcid: 9913598
doi: 10.3390/cancers15030974
Solimando AG, Krebs M, Bittrich M, Einsele H. The urgent need for precision medicine in cancer and its microenvironment: the paradigmatic case of multiple myeloma. J Clin Med. 2022;11:5461.
pubmed: 36143110
pmcid: 9502417
doi: 10.3390/jcm11185461